Multidisciplinary Head and Neck Cancer Symposium | Conference

Dr. Nussenbaum on Organ Preservation for Patients With Larynx Cancer

August 10th 2016

Brian Nussenbaum, MD, Christy J. and Richard S. Hawes III Professor, Otolaryngology-Head and Neck Surgery, director, Head and Neck Surgical Oncology, vice chair of Clinical Affairs, patient safety officer, Washington University School of Medicine in St. Louis, discusses which patients with larynx cancer are eligible for organ preservation surgery.

Dr. Schoenfeld on Immunologic Effects of Chemotherapy and Radiation in Head and Neck Cancer

March 9th 2016

Jonathan D. Schoenfeld, MD, MPH, physician, assistant professor of Radiation Oncology, Harvard Medical School, Dana Farber Cancer Center on the immunologic effects of chemotherapy and radiation in head and neck cancer.

Dr. Cohen on Lenvatinib in First- or Second-Line Thyroid Cancer

March 9th 2016

Ezra Cohen, MD, Associate Director, Professor of Medicine Moores Cancer Center, UC San Diego, discusses if lenvatinib should be used in the frontline or second-line setting in differentiated thyroid cancer.

Dr. Adelstein on Adjuvant Therapy for Oral Cancer

March 8th 2016

David Adelstein, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses adjuvant therapy options for patients with oral cancer.

Dr. Randal Weber on Future Treatment Approaches for Patients With Melanoma

March 1st 2016

Randal S. Weber, MD, FACS, professor, department chair, John Brooks Williams and Elizabeth Williams Distinguished University Chair in Cancer Medicine, Department of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses future treatment approaches for patients with melanoma.

Dr. Frakes on Managing Late Toxicities Associated With Treatment for HPV+ Oropharyngeal SCC

February 26th 2016

Jessica Frakes, MD, assistant professor of Radiation Oncology, Department of Radiation Oncology, Moffitt Cancer Center, discusses management of toxicities associated with treatment of patients with HPV-positive oropharyngeal squamous cell carcinoma.

Dr. Martins on Managing Toxicities Associated With Lenvatinib in DTC

February 25th 2016

Renato G. Martins, MD, medical director of Outpatient General Oncology/Hematology at Seattle Cancer Care Alliance, medical director of Thoracic/Head and Neck Oncology, and professor at the University of Washington School of Medicine, discusses side effects that are associated with lenvatinib (Lenvima).

Immunotherapy Continues to Advance in Head and Neck Cancer

February 23rd 2016

An early-stage trial is examining the addition of nivolumab to a cetuximab regimen in head and neck squamous cell carcinoma.

Pazopanib/Cetuximab Combo Shows Promising Efficacy in Advanced HNSCC

February 23rd 2016

The combination of pazopanib (Votrient) and cetuximab (Erbitux) showed a disease control rate of 77% in patients with recurrent or metastatic head and neck squamous cell carcinoma, including patients with cetuximab- or platinum-resistant disease.

Cetuximab Improves Long-Term Control in HPV-Negative Head and Neck Cancer

February 22nd 2016

Among patients with HPV-negative, locoregionally advanced head and neck squamous cell carcinoma with a poor prognosis, adding cetuximab (Erbitux) to induction chemotherapy and hyperfractionated or accelerated chemoradiation therapy produced long-term control.

x